# Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

> **NCT03992755** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Liquidia Technologies, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Primary Pulmonary Hypertension

## Interventions

- **DRUG:** LIQ861 Inhaled Treprostinil

## Key facts

- **NCT ID:** NCT03992755
- **Lead sponsor:** Liquidia Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-18
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992755, "Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03992755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*